CAMBRIDGE, Mass., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting™, today announced it will provide an update on corporate activities for the third quarter of 2014 on November 13.
Paul Friedman, M.D., Executive Chairman and Chris Guiffre, Chief Operating Officer will conduct a conference call at 4:30 p.m. (ET) that day to provide a business update and review the Company's third-quarter financial results. The call can be accessed by dialing (844) 831-3031 or (443) 637-1284 prior to the start of the call and referencing conference ID: 25500996. The conference call will also be webcast live over the Internet and can be accessed on the "Investors" section of the Cerulean website, www.ceruleanrx.com. The webcast will be archived on the Company's website for two weeks.
About Cerulean Pharma
The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of nanoparticle-drug conjugates, or NDCs, designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Our lead product candidate, CRLX101, is in multiple clinical trials with other cancer treatments, all of which aim to unlock the power of combination therapy. For more information, please visit www.ceruleanrx.com.
CONTACT: Aurora Krause Cerulean Pharma Inc. Corporate Communications 617-551-9627
Source:Cerulean Pharma Inc.